Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology, cilt.32, ss.1127-1136, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32
- Basım Tarihi: 2021
- Doi Numarası: 10.1016/j.annonc.2021.05.803
- Dergi Adı: Annals of oncology : official journal of the European Society for Medical Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
- Sayfa Sayıları: ss.1127-1136
- Anahtar Kelimeler: pembrolizumab, chemotherapy, tumor mutational burden, gastroesophageal adenocarcinoma, gastric cancer, TUMOR MUTATIONAL BURDEN, TISSUE TMB TTMB, CTLA-4 BLOCKADE, PD-1 BLOCKADE, BENEFIT, PEMBRO, NSCLC, CHEMO
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.